Sentences with phrase «in diabetes therapy»

Thus, our projects addressing beta cell function aim to reveal the underlying mechanisms of functional compensation and beta cell dysfunction to protect and recover beta cell function in diabetes therapy.

Now, scientists reporting April 12 in Cell Metabolism have discovered a protein that activates the maturation process in vitro, overcoming this longstanding obstacle in diabetes therapy development.

She continued: «Therefore, in further studies, we should investigate how and at what point DPP4 inhibitors can be used in diabetes therapy to prevent the development of non-alcoholic fatty liver disease.»

Not exact matches

About Blog iPAG Scotland is a group made up of pump users, potential pump users or parents of children with Type 1 Diabetes interested in Insulin Pump Therapy & New Technology.

Non-lactational mastitis occurs in women with weakened immune systems, including women who have had lumpectomies with radiation therapy and women with diabetes.

The findings suggest that fenofibrate therapy may be beneficial in the way the researchers hoped: by reducing cardiovascular events in patients with type 2 diabetes who take statins but still have especially high triglycerides levels and low HDL cholesterol levels.

«We envision that our nanoparticle therapy could be used to speed the healing of all sorts of wounds, including everyday cuts and burns, surgical incisions, and chronic skin ulcers, which are a particular problem in the elderly and people with diabetes,» said study co-leader David J. Sharp, Ph.D., professor of physiology & biophysics at Einstein.

The trial included 501 patients with atherosclerotic cardiovascular disease (ASCVD) and elevated LDL cholesterol (> 70mg / ml) despite maximum tolerated statin therapy and patients without ASCVD but with high cardiovascular risk conditions such as diabetes and familial hypercholesterolaemia in whom LDL cholesterol was > 100mg / dl despite maximally tolerated statin therapy.

In addition, the development of therapies that could potentially halt patients» progression from pancreatic inflammation to diabetes has been hampered by the long lead times needed in order to tell whether a given therapy has an effecIn addition, the development of therapies that could potentially halt patients» progression from pancreatic inflammation to diabetes has been hampered by the long lead times needed in order to tell whether a given therapy has an effecin order to tell whether a given therapy has an effect.

«Using Streptozotocin - induced type I diabetes and cornea epithelial wounding experimental models, we made novel observations that may soon lead to innovative therapies to treat DPN and ulcerations of the cornea and skin in diabetic patients,» said Yu.

«In further studies we want to examine how different combination therapies affect the retinal proteins, in order to achieve a better understanding of the causes and treatment of this diabetes complication,» added Dr. Stefanie Hauck (PROTIn further studies we want to examine how different combination therapies affect the retinal proteins, in order to achieve a better understanding of the causes and treatment of this diabetes complication,» added Dr. Stefanie Hauck (PROTin order to achieve a better understanding of the causes and treatment of this diabetes complication,» added Dr. Stefanie Hauck (PROT).

Researchers at New York University College of Dentistry (NYU Dentistry) have described a new target that may open the door to developing therapies for preventing bone fractures in people with type 2 diabetes.

Experiments with a compound called TNP [N2 -(m - Trifluorobenzyl), N6 -(p - nitrobenzyl) purine], which researchers often use to study obesity and diabetes, show that in mice the therapy can promote the formation of new bone.

The U.S. attorney's office in Indianapolis had alleged that Guoqing Cao and Shuyu Li, both naturalized U.S. citizens and senior biologists at Eli Lilly, passed research on tailored therapies for cancer and drugs to treat diabetes, obesity, and other metabolic disorders to Jiangsu Hengrui Medicine, a company in Lianyungang, China.

Diabetes researchers are considering various replacements for insulin injections: Transplanting new pancreatic islet cells that make insulin, coaxing the patient's own islets to regenerate, or treating diabetics early in the disease with immune - suppressing therapies to prevent their body from destroying the rest of their pancreatic islets.

The study, «AKR1B1 promotes basal - like breast cancer progression by a positive feedback loop that activates the EMT program,» which has been published in The Journal of Experimental Medicine, suggests that an inhibitor of this enzyme currently used to treat diabetes patients could be an effective therapy for this frequently deadly form of cancer.

If the therapy can be improved and shown to work well in humans, it could be an entirely new way to help battle obesity, diabetes and related conditions.

The new method of estimating blood sugar could also help researchers evaluate new therapies for diabetes in clinical trials, he noted.

Biopharmaceutical drugs, which are used in a wide range of therapies including vaccines and treatments for diabetes and cancer, are typically produced in large, centralized fermentation plants.

Antigen - specific therapy using insulin before the development of autoantibodies may induce protective immune responses that prevent the emergence of autoimmunity and subsequent type 1 diabetes in genetically at - risk children, according to background information in the article.

The promise of autoantigen - specific therapy for prevention of type 1 diabetes in humans has yet to be realized.

«While expanding beta cell mass may still be desirable for future diabetes therapy, improving the local environment of the otherwise healthy aged beta cell could prevent age - associated deterioration in glucose homeostasis and thereby promote healthy ageing, which is conceptually novel and highly exciting,» says Per - Olof Berggren.

Even with insulin therapy, people with type 1 diabetes frequently experience fluctuations in blood sugar levels.

In the late 1990s medical researchers at NIDDK and in Finland conducted trials combining exercise, diet, and drug therapy as a way to head off diabetes in overweight people with high blood sugaIn the late 1990s medical researchers at NIDDK and in Finland conducted trials combining exercise, diet, and drug therapy as a way to head off diabetes in overweight people with high blood sugain Finland conducted trials combining exercise, diet, and drug therapy as a way to head off diabetes in overweight people with high blood sugain overweight people with high blood sugar.

Scientists have been investigating molecular pathways that govern beta cell growth in hopes of finding new therapies that would help people regain blood glucose control after the onset of diabetes.

A growing body of evidence suggests that rapid detection of, and aggressive new therapies for, type - 1 diabetes benefit patients in the long run, possibly halting the autoimmune attack on the pancreas and preserving some of the body's ability to make insulin.

But in patients with type 1 diabetes, beta - cell replacement therapy is likely doomed to failure because the new cells might fall victim to the same autoimmunity that destroyed the original cells.

«The addition of osteocalcin as a metabolic regulator may one day lead to novel therapies, but we need to understand much better how it works and how it fits into physiology before such therapies can be attempted in humans,» says endocrinologist Mitch Lazar, director of the Institute for Diabetes, Obesity, and Metabolism at the University of Pennsylvania.

A study published January 4th in Cell Stem Cell demonstrates that a gene therapy approach can lead to the long - term survival of functional beta cells as well as normal blood glucose levels for an extended period of time in mice with diabetes.

«With the new test, not only do we anticipate being able to diagnose diabetes more efficiently and more broadly, we will also understand diabetes better — both the natural history and how new therapies impact the body,» said Brian Feldman, MD, PhD, assistant professor of pediatric endocrinology and the Bechtel Endowed Faculty Scholar in Pediatric Translational Medicine.

«A clinical trial in both type 1 and type 2 diabetics in the immediate foreseeable future is quite realistic, given the impressive nature of the reversal of the diabetes, along with the feasibility in patients to do AAV gene therapy.»

Two teams of scientists suggest that activating immune cells in fat can convert the tissue from a type of fat that stores energy to one that burns it, opening up potential new therapies for obesity and diabetes.

And that in turn opens up some intriguing possibilities for treating obesity and diabetes, such as giving a therapy like Metrnl, if it turns out to be safe and effective, that can brown white fat.

«This drop in A1C due to nutrition therapy alone is much better than what we have been able to achieve with many of the current medications for type 2 diabetes,» said Dr. Hamdy.

Verchere also believes IAPP is «a big player» in the progression of type 2 diabetes, and that therapies that prevent the clumps of proteins from forming are needed.

Raydiance's technology has attracted the attention of the U.S. Food and Drug Administration (FDA), which in July 2007 signed the company to a two - year cooperative research and development agreement that has allowed the FDA's Center for Devices and Radiological Health (CDRH) to evaluate the use, safety and effectiveness of Raydiance's USP laser system in a number of areas, including the ablation of corneal tissues in refractive surgery and corneal repair; the administration of light therapy for treating cancer, cardiovascular disease and diabetes; and the removal of plaque on teeth without damaging the enamel.

With these findings, Helmholtz Zentrum München scientists have discovered key molecular functions of stem cell differentiation which could be used for beta cell replacement therapy in diabetes.

Scientists from the Helmholtz Zentrum München have reported in the journal Diabetes Care that high - affinity GAD antibodies are found in patients who produce only a little of their own insulin and who will require insulin therapy after only a relatively short time.

The team provides personalized medication therapy management and patient - specific diabetes education in one - hour visits.

Solt notes that the study strongly suggests that Th17 cells have a pathological role in the development of type 1 diabetes and use of ROR - specific synthetic compounds targeting this cell type may have potential as a preventative therapy for type 1 diabetes.

A new model for post-integration latency in macroglial cells to study HIV - 1 reservoirs of the brain, AIDS, DOI: 10.1097 / QAD.0000000000000691 Link to the original publication As German Research Center for Environmental Health, Helmholtz Zentrum München pursues the goal of developing personalized medical approaches for the prevention and therapy of major common diseases such as diabetes mellitus and lung diseases.

The University's Physical Therapy Clinics treat many individuals in this age group with recently developed knee pain, both with and without Type 2 diabetes mellitus, White said.

Previous randomised trials comparing the efficacy of insulin pump therapy and multiple injections in people with type 2 diabetes have not provided consistent evidence, and the benefits of pump therapy continue to be debated.

This work provides direct evidence in mice that cyclin D2 is needed for a successful response to a broad spectrum of insulin resistance, and points toward potential therapies that can be harnessed for preventing and curing type 2 diabetes.

The implications of these data are that maternal treatment with antioxidants may provide possible therapy against the programming effects on vascular dysfunction in pregnancy complicated by fetal hypoxia, such as during placental insufficiency, preeclampsia, gestational diabetes or high altitude pregnancy.

Regardless of the targeted organ for cell replacement or regeneration, the shared challenges in cell therapies for diabetes such as transplant procedure and immune rejection will be well - served by the collective expertise within CCTD.

Zucara Therapeutics, a spin - off company by The Centre for Drug Research and Development (CDRD) and MaRS Innovation (MI), is developing the first drug therapy to prevent hypoglycemia in people with diabetes.

«It is a unique opportunity for us to work with the Helmsley Charitable Trust, an organization that is deeply involved in bringing Type 1 diabetes (T1D) technologies and therapies to people with the disease and has strong connections in the diabetes community.

The PEC - Encap ™ (also known as VC - 01) product candidate is designed to deliver the same pancreatic progenitor cells in an immunoprotective device and is currently in active development as a therapy for all patients with type 1 diabetes as well as insulin requiring patients with type 2 disease.

Better understanding of the beta - cell proliferation process eventually may lead toward therapies for diabetes patients, whose supplies of these cells often shrink over time, says Rohit Kulkarni, M.D., Ph.D., a Joslin Senior Investigator and senior author on a paper about the work published in the journal Cell Metabolism.